CN100418516C - 包括预成形水凝胶产品的即用即制装置 - Google Patents
包括预成形水凝胶产品的即用即制装置 Download PDFInfo
- Publication number
- CN100418516C CN100418516C CNB2004800161900A CN200480016190A CN100418516C CN 100418516 C CN100418516 C CN 100418516C CN B2004800161900 A CNB2004800161900 A CN B2004800161900A CN 200480016190 A CN200480016190 A CN 200480016190A CN 100418516 C CN100418516 C CN 100418516C
- Authority
- CN
- China
- Prior art keywords
- preform
- hydrogel
- component
- skin
- useful component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000017 hydrogel Substances 0.000 title claims description 135
- 239000000203 mixture Substances 0.000 claims abstract description 69
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 230000008901 benefit Effects 0.000 claims abstract description 26
- 229920001282 polysaccharide Polymers 0.000 claims description 44
- 239000005017 polysaccharide Substances 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 239000003349 gelling agent Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- -1 ascorbic acid compound Chemical class 0.000 claims description 23
- 235000010323 ascorbic acid Nutrition 0.000 claims description 17
- 239000011668 ascorbic acid Substances 0.000 claims description 17
- 229960005070 ascorbic acid Drugs 0.000 claims description 16
- 230000009286 beneficial effect Effects 0.000 claims description 15
- 239000000843 powder Chemical class 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 12
- 230000003319 supportive effect Effects 0.000 claims description 6
- 230000000476 thermogenic effect Effects 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 238000004049 embossing Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims 2
- 210000004209 hair Anatomy 0.000 abstract description 17
- 229920000642 polymer Polymers 0.000 abstract description 8
- 239000004094 surface-active agent Substances 0.000 abstract description 3
- 239000003093 cationic surfactant Substances 0.000 abstract description 2
- 230000003750 conditioning effect Effects 0.000 abstract 5
- 239000008365 aqueous carrier Substances 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 238000000518 rheometry Methods 0.000 abstract 1
- 230000008719 thickening Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 75
- 239000000047 product Substances 0.000 description 59
- 150000004804 polysaccharides Chemical class 0.000 description 42
- 239000000499 gel Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 16
- 210000004905 finger nail Anatomy 0.000 description 13
- 238000012856 packing Methods 0.000 description 13
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 11
- 229920000926 Galactomannan Polymers 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 10
- 229920001206 natural gum Polymers 0.000 description 10
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 9
- 241001661616 Bostrychia montagnei Species 0.000 description 9
- 229920002581 Glucomannan Polymers 0.000 description 9
- 229940046240 glucomannan Drugs 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 241001597008 Nomeidae Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 241000199919 Phaeophyceae Species 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000007789 gas Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 150000005846 sugar alcohols Polymers 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 229920003169 water-soluble polymer Polymers 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920000161 Locust bean gum Polymers 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940122511 Sebum inhibitor Drugs 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000010420 locust bean gum Nutrition 0.000 description 3
- 239000000711 locust bean gum Substances 0.000 description 3
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 3
- 125000000185 sucrose group Chemical group 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- MLSJBGYKDYSOAE-BEVZWNRGSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-4-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2h-furan-5-one Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OC2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-BEVZWNRGSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000001884 Cassia gum Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000019318 cassia gum Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000008199 coating composition Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940025902 konjac mannan Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000012744 reinforcing agent Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 231100000051 skin sensitiser Toxicity 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000003856 thermoforming Methods 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 240000000972 Agathis dammara Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000179442 Anacharis Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000206576 Chondrus Species 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000016649 Copaifera officinalis Species 0.000 description 1
- 239000004859 Copal Substances 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 235000008222 Cyamopsis psoralioides Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229920002871 Dammar gum Polymers 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000937378 Everettia interior Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical group OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- 241001516928 Kerria lacca Species 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Chemical group OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000201976 Polycarpon Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010007568 Protamines Chemical class 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108050007496 Shikimate kinase 2 Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920002310 Welan gum Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229940054190 hydroxypropyl chitosan Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 229940100556 laureth-23 Drugs 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 1
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 1
- 239000000467 phytic acid Chemical group 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical class [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910000031 sodium sesquicarbonate Inorganic materials 0.000 description 1
- 235000018341 sodium sesquicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种包括预成形水凝胶产品的即用即制装置,所述装置包含包装在第一隔室内的预成形水凝胶组分;所述预成形水凝胶组分包含胶凝剂和溶剂;和包装在第二隔室内的有益组分;所述有益组分包含至少一种化合物,所述化合物在与所述预成形水凝胶组分接触时不稳定;其中所述第一和第二隔室在使用前分别包装,并且其中所述装置包括在使用时接触预成形水凝胶组分和有益组分的部件。本发明的装置能够提供一种能够与多种化合物配制时能被消费者适当使用的稳定的预成形水凝胶产品。
Description
发明领域
本发明涉及一种即用即制装置,其包括至少2个单独的包含临时组分的隔室,该临时组分在使用时相互接触。所述临时组分是预成形的水凝胶组分和有益组分。所述装置适于递送当与预成形水凝胶组分接触时不稳定的组分,还适于以合适的方式即用即制最终的预成形水凝胶产品。
发明背景
由胶凝剂制成的预成形水凝胶因其成形的但柔韧的物理特性而向多种消费品提供独特的有益效果。预成形水凝胶贴剂和面膜装置可用于化妆品和皮肤病处理产品,如用于递送护肤活性物质、经皮递送的药物和促进烧伤或创伤的愈合。可食用的预成形水凝胶片和物品提供具有独特外观、味道和口感的营养产品和小吃;以及口服药物。
尤其是在护肤领域,专业化妆品如贴剂和面膜的使用正日益普及,这是因为它们与其它处理例如化学换肤、激光手术、光子嫩肤和其它相比更有效、相对安全并且价格合理。PCT公布WO 01/78678及共同未决的美国申请60/339287涉及将皮肤有益剂有效递送到皮肤、毛发或指甲上的预成形水凝胶产品,该装置包含呈预成形水凝胶涂层组合物形式的皮肤有益剂。
尽管这些预成形水凝胶产品适于将多种皮肤有益剂递送到皮肤上,但有某些皮肤有益剂和其它化学化合物不能与该产品配制,这是因为它们与预成形水凝胶接触时不稳定。例如,某些化合物与预成形水凝胶反应并增强脱水收缩作用、提高硬度或产生不美观的颜色和/或气味。所有这些结果都可能会显著地影响产品的性能和/或美观。此类因素限制了能够与预成形水凝胶产品配制的化合物范围。
基于前文所述,需要一种能够与多种化合物配制的并且能被消费者适当使用的预成形水凝胶产品。此外,还需要能够以低成本提供的此类产品。
没有任何现有技术能提供本发明的全部优点和有益效果。
发明概述
本发明涉及即用即制装置,该装置包含:
(1)包装在第一隔室内的预成形水凝胶组分,该预成形水凝胶组分包含胶凝剂和溶剂;和
(2)包装在第二隔室内的有益组分,该有益组分包含至少一种当与预成形水凝胶组分接触时不稳定的化合物;
其中第一和第二隔室在使用前分别包装,并且其中该包装包括在使用时用于接触预成形水凝胶组分和有益组分的部件。
本发明还涉及一种装置,其中预成形水凝胶组分具有带有指定纹理的第一表面,并且有益组分具有指定粘度。
通过阅读下面的描述和所附的权利要求书,可更好地理解本发明的这些和其它的特征、方面和优点。
附图概述
虽然本说明书以特别指出和清楚地限定本发明保护范围的权利要求书作为结尾,但是应该相信由下列优选描述、非限制性实施方案以及与附图结合的陈述,可更好地理解本发明:
图1是本发明装置的一个优选实施方案的剖面图,其中包装材料的厚度被膨胀。
图2是本发明装置的一个优选实施方案的透视图,其中密封衬料刚刚移除。
图3是本发明包装的一个优选实施方案的透视图。
图4是本发明装置在制备期间的一个优选实施方案的剖面图。
图5是本发明装置的一个优选实施方案的另一个剖面图,其中已完成最终产品的制备。
图6是本发明装置为一系列单元的一个优选实施方案的透视图。
定义
所有引用的参考文献均全文引入本文以供参考。任何文献的引用并不是认可其可作为要求保护的本发明的现有技术获得。
本文中,“包括”是指可加入不影响最终结果的其它步骤和其它成分。该术语包括术语“由...组成”和“基本上由...组成”。
除非另外说明,所有的百分比、份数和比例均以本发明的组合物的总重量计。所有涉及所列出成分的重量均是以其活性物质含量计,并且因此不包括可能包含在市售产品中的载体或副产物。除非另外指明,所有量度都在25℃下进行。
可用于本发明的所有成分(如活性物质和其它成分)可根据其化妆和/或治疗有益效果或其假定的作用模式来分类或描述。然而,应当理解,在某些情况下可用于本发明的活性物质和其它成分可以提供一种以上的美容和/或治疗有益效果或通过一种以上的作用方式起作用。因此,本文的分类只是为了方便,并非旨在将成分限制在所列的特别指出的一个应用或几个应用中。
本文所用术语“预成形”是指物品被制造成具有预定形状和尺寸的形式,其中该物品可用手指从任何相关包装中取出和放置或覆盖在目标表面,而无需使用者的进一步制备性步骤。术语“预成形”还指当制造完成后,将其铺展在平坦表面上时,物品在所需正常储存温度下基本保持其形状。当施用到不平坦表面上或如果受到挤压时,组合物也可能弯曲或变形。
本文所用术语“不含支持性基质”是指预成形水凝胶在组合物中是均匀和单层的,没有其它用于辅助预成形水凝胶的结构或完整性的基质或层。
发明详述
尽管本说明书以由特别指出并清楚地要求保护本发明的权利要求书作出结论,但应该相信由以下说明可更好地理解本发明。
即用即制装置
本发明涉及被具体设计成即用即制最终产品的装置,典型地是在使用前约60分钟内,优选约10分钟内,可恰当地称作“即用即制”产品。即用即制装置在本领域内是已知的,并包括至少2个单独的包含临时组分的隔室,该临时组分在使用时相互接触。设计即用即制装置使得临时组分在存储期间不相互接触。此外,优选设计用于即用即制装置的包装使得可利用该包装的隔室之一制备最终产品,例如混合临时产品。
本发明涉及适于向使用者递送到少两种临时组分的此类即用即制装置,所述临时组分为至少一种预成形水凝胶组分和一种有益组分,所述有益组分当与预成形水凝胶组分接触时不稳定。参考图1,本装置(10)包括至少两个分别包装临时组分的隔室,临时组分即第一隔室(20)内的预成形水凝胶组分(21)和第二隔室(30)内的有益组分(31)。本文的预成形水凝胶组分典型地相对易受湿度改变,尤其是易受过量或快速干燥影响。干燥超过一定程度时,取决于组合物,将通过破坏其凝胶结构使预成形水凝胶分解和变形。因此,本装置的包装由具有低水汽渗透性的材料制成,以将临时组分的干燥最小化。第一和第二隔室可由相同的具有凹形开口(凹形开口彼此相距足够远)的相对刚性的塑性材料片制成,且用常见的可分离衬料(40)密封,该衬料由例如塑性铝或层压薄膜制成。
本发明的装置也用于以合适的方式即用即制最终预成形水凝胶产品,即以使用者容易执行的方式。在隔室之一内制备最终预成形水凝胶产品,其中临时组分被最初包装在隔室内,优选有益组分被最初包装在第二隔室内。本装置的包装包括使用时接触预成形水凝胶组分和有益组分的部件。图2描述了刚刚移除密封衬料(40)的本装置的一个优选实施方案。预成形水凝胶组分(21)位于第一隔室(20)内,有益组分(31)位于第二隔室(30)内。转回参考图1,凹口区域(50)穿过分开第一和第二隔室的材料。此类凹口区域用于轻微弱化材料使得其能被使用者折叠而不会完全破裂,如图4中所描述。通过这种折叠,使用者可使预成形水凝胶组分和有益组分相互接触,而不接触预成形水凝胶组分或有益组分。此类制备从卫生角度来讲是合适的,因这样可避免来自手的污染。包装的整个构型从制造费用观点也是合适的,因为该包装可用常用的材料和常规的热成型技术制成。
在一个优选的操作模式中,如图4和图5所描述,将预成形水凝胶组分从第一隔室转移到第二隔室。因此转移到第二隔室的预成形水凝胶组分接触有益组分以提供最终的水凝胶产品,该产品可由使用者获得。使用者可进一步接合或浸泡预成形水凝胶组分至有益组分中以更好地得到有益组分。参考图3,第一隔室的内表面(22)可包括压花(23)以有利于预成形水凝胶组分在转移到第二隔室内时的释放。第二隔室的内表面(32)也可包括压花以有利于最终产品的制备,例如,当使用者将水凝胶组分接合在有益组分中时避免该水凝胶滑出第二隔室。
本发明的装置可以单独的单元或者以图6所描述的一连串单元提供。图6中的连串装置以4组/套提供,其中每个单元可通过破坏多孔区(60)分开。提供连串装置有利于提供在固定时段例如一天内计划给予的剂量,和/或只是有利于减少次级包装材料。
预成形水凝胶组分
本发明的装置包含预成形水凝胶组分。本发明的预成形水凝胶组分提供结构和形状,使得其能够被处理并适合皮肤、毛发或指甲、织物或硬质表面的具体目标区域的处理,或者被口服或消费。设计物理特性如强度、柔韧性和表面纹理以满足预成形水凝胶组分打算实现的功能。
对于局部应用,预成形水凝胶还可作为皮肤、毛发或指甲的皮肤有益剂、药物或美学化妆剂的贮存器或作为递送载体。此外,当涂敷于皮肤、毛发或指甲时,由于溶剂的蒸发作用,预成形水凝胶可在使用期间向物品提供冷却作用。在食品或口服药物领域,预成形水凝胶可提供风味、味道、营养或某些药物活性物质。在非个人护理领域,其还可作为包含织物或硬质表面处理剂(如移除/吸收色斑的溶剂、去污表面活性剂和漂白剂)的贮存器或作为递送载体。预成形水凝胶可具有或不具有支持性基质。
胶凝剂
本发明的预成形水凝胶包含提供结构和形状的胶凝剂。根据胶凝剂的性质,包括在预成形水凝胶中的胶凝剂的种类和数量可根据产品所需特性和用途来选择。通常,胶凝剂越多,提供的预成形水凝胶的刚性就越大。为了提供食品或口服品,胶凝剂必须是可食用的并且在味道和风味方面是可接受的。许多种胶凝剂是本领域已知的,包括聚合胶凝剂和颗粒基的胶凝剂,如各种类型的粘土或其它硅酸盐基物质。本文高度优选的是与水结合形成三维凝胶网络的聚合胶凝剂。为了提供化妆品装置,预成形水凝胶优选包含约0.5%至约20%,更优选约1%至约10%的胶凝剂。
本发明胶凝剂可以是水溶性的或水不溶性的并根据溶剂选择。当溶剂是水或水基时,优选胶凝剂是水溶性的。水不溶性的聚合胶凝剂,如硅氧烷物质(例如有机聚硅氧烷树脂)或嵌段共聚物热塑性弹性体可在适当的溶剂中使用。
可用于本发明的水溶性聚合物胶凝剂选自合成的或天然的聚合物、以及它们的混合物。可用于本文的优选聚合物是天然聚合物,包括明胶、多糖、以及它们的混合物。优选的是多糖。本文所用术语“多糖”是指天然存在或合成的单糖单元的直链、支链或交联聚合物,当其以低浓度分散在水中时膨胀并使水相变稠。
用于本发明预成形水凝胶的多糖优选选自红海藻多糖、葡甘露聚糖、半乳甘露聚糖、发酵多糖或其衍生物、褐海藻多糖、海洋无脊椎动物提取物、淀粉或其衍生物、天然果实提取物、植物纤维衍生物、海藻;天然植物渗出物、和树脂树胶或它们的混合物。控制总多糖含量以便预成形水凝胶的其它非必需组分不被紧密地束缚在凝胶网络中并可以扩散。
当明胶用于本文预成形水凝胶中时,高分子量明胶与低分子量明胶结合使用以便控制溶解度。当单独用作胶凝剂时,分子量低于20,000或更小的明胶具有较差的胶凝化能力。
褐海藻多糖是从各种褐海藻提取物中分离出来的。可用于本文的褐海藻多糖包括褐海藻胶、藻酸、藻酸铵、藻酸钙、藻酸钾、藻酸钠、丙二醇藻酸盐、以及它们的混合物。
红海藻多糖是从属于红藻纲的海生植物物种中分离出来的。红海藻多糖为预成形水凝胶提供机械强度。适用于本发明的红海藻多糖包括工业中已知的(CTFA)商业命名为琼脂琼脂片的琼脂,衍生自各种石花菜属植物物种或以商品名“Agar Agar 100”或“Agar Agar 150”购自TIC Gums(Belcamp,MD,USA)或“Agar Agar K-100”购自GumixInternational Inc.(Fort Lee,NJ,USA)的密切相关的红海藻类;以商品名“Sea Plaque”购自FMC(Philadelphia,PA,USA)和“Agarose Type 1-b”购自Sigma-Aldrich Co.Ltd.(Poole,UK)的琼胶糖;角叉菜胶,包括部分λ-、ι-和κ-角叉菜胶,其是得自杉藻科或红翎菜科各部分的水提取物,工业中已知的是(CTFA)商业命名的角叉菜属,以商品名“GelcarinLA”、“Seakem3/LCM”或“ViscarinXLV”购自FMC(Philadelphia,PA,USA);和由GumTechnology Corporation(Tucson,Arizona,USA)和ContinentalColloids Inc.(Chicago,IL,USA)市售的帚叉藻聚糖胶,或它们的混合物。优选地,可用于本文的红海藻多糖选自琼脂、琼脂糖、κ角叉菜胶和帚叉藻聚糖胶或它们的混合物。
葡甘露聚糖是包括葡萄糖和甘露糖残基的基本上直链主链的多糖。葡甘露聚糖具有较短的连接到直链主链上的侧链和随机地存在于蔗糖单元的C-6位的乙酰基。通常每六个蔗糖单元至每二十个蔗糖单元有一个乙酰基。可用于本文的合适葡甘露聚糖或其衍生物的甘露糖和葡萄糖的比率为约0.2至约3。可用于本文的优选葡甘露聚糖包括魔芋甘露聚糖,其是由研磨魔芋植物(象薯蓣)的块茎根部形成的粉末的通用名,以商品名“NutricolKonjac flour”购自FMC(Philadelphia,PA,USA);和脱乙酰基魔芋甘露聚糖;或它们的混合物。
半乳甘露聚糖是出现在豆科植物类的许多种子的胚乳细胞中的植物储备多糖。统称术语“半乳甘露聚糖”包括所有由半乳糖和甘露糖残基构成的多糖。半乳甘露聚糖包括(1→4)-连接β-D-吡喃甘露糖基单元的直链主链。被α-(1,6)-葡糖苷键分离的吡喃半乳糖残基被作为支链连接到这些环上。半乳甘露聚糖还可以另外包含微量的其它糖残基。可用于本文的合适半乳甘露聚糖是胡芦巴树胶、苜蓿、三叶草、例如工业中已知的(CTFA)商业命名为角豆胶的刺槐豆胶,以商品名“Seagul L”购自FMC(Philadelphia,PA,USA)、购自StarlightProducts(Rouen,France)或Bunge Foods(Atlanta,GA,USA)的塔拉胶;衍生自瓜尔豆(Cyamopsis tetragonolobus)的基本胚乳的瓜耳胶,以商品名“Burtonite V7E”购自TIC Gums(Belcamp,MD,USA),“Jaguar C”购自Rhone-Poulenc(Marietta,GA,USA),或以商品名“Supercol”购自Aqualon(Wilmington,DE,USA);和购自Starlight Products(Rouen,France)的肉桂树胶或它们的混合物。优选地,可用于本文的半乳甘露聚糖平均每1至约5个甘露糖单元中有一个被(1→6)-连接的-α-D-吡喃半乳糖单元取代并选自瓜耳胶、刺槐豆胶和肉桂树胶或它们的混合物。
发酵多糖是通过在包含碳和氮源、缓冲剂和痕量元素的介质中微生物发酵生产的市售多糖。用于本发明的合适发酵多糖或其衍生物包括工业中已知的(CTFA)商业命名为树胶凝胶的结冷胶,其为由碳水化合物和假单胞菌属伊乐藻属植物的纯培养物发酵生产的高分子量的杂多糖树胶,可以商品名“Kelcogel”购自Kelco(San Diego,CA,USA);由碳水化合物和野生黄单胞菌属的纯培养物发酵生产的高分子量杂多糖树胶黄原胶,工业中(CTFA)商业命名为黄原胶,可以商品名例如“Keltrol CG 1000/BT/F/GM/RD/SF/T/TF”购自Calgon(Pittsburgh,PA,USA),或“Kelzan”购自Kelco(San Diego,CA,USA);纳豆树胶;普鲁兰多糖;鼠李聚糖胶;凝胶多糖;琥珀酰聚糖;文莱胶;以商品名“Sephadex G-25”购自Pharmacia Fine Chemicals(Piscataway,NJ,USA)的葡聚糖和其衍生物;和以商品名“Amigel”购自Alban Muller International(Montreil,France)的菌核树胶或它们的混合物。优选的发酵多糖或其衍生物选自结冷胶和黄原胶或它们的混合物。更优选地发酵多糖或其衍生物是黄原胶。
也可使用海洋无脊椎动物的提取物。衍生自海洋无脊椎动物,具体地讲是衍生自此类无脊椎动物的外骨骼的多糖,主要由N-乙酰基-D-葡糖胺残基构成。适用于本发明的这种多糖的实施例包括脱乙酰壳多糖,例如以“Marine Dew”购自Ajinomoto(Teakneck,NJ,USA);和羟丙基脱乙酰壳多糖,例如以“HPCH Liquid”购自Ichimaru Pharcos(Yamagata Gun Gifu-Pref,Japan)及其衍生物;或它们的混合物。
淀粉是由各种比例的双葡萄糖聚合物、直链淀粉和支链淀粉组成的多糖。可用于本文的合适物质包括淀粉、支链淀粉和糊精,以商品名“Nadex 360”购自National Starch(Bridgewater,NJ,USA),和其衍生物或混合物。适用于本文的天然果实提取物的实施例包括果胶、阿拉伯胶、以及它们的混合物。可用于本文的植物纤维衍生物的合适实施例是纤维素。可用于本文的得自天然植物提取物的合适多糖包括刺梧桐树胶、黄蓍胶、阿拉伯胶、罗望子和茄替胶或它们的混合物。适用于本文的树脂树胶的实施例包括紫胶树胶,其得自昆虫紫胶虫虫胶的树脂分泌物、达玛树脂树胶;古巴树脂树胶和松香树胶;或它们的混合物。
与其它物质组合形成凝胶的天然的和合成的聚合胶凝剂也可与其它热成型胶凝剂联合用作胶凝剂,只要凝胶相的形成能够同步。它们可以是化学交联的。一些胶凝剂与物质如糖、醇、或一价或多价盐结合形成凝胶。一价或多价盐还可另外作为凝胶强化剂,赋予本文预成形水凝胶附加的强度。适于这种盐的阳离子可以选自钾、钠、铵、锌、铝、钙和镁离子或它们的混合物。与上述阳离子结合的合适阴离子可选自氯离子、柠檬酸根、硫酸根、碳酸根、硼酸根、和磷酸根阴离子或它们的混合物。
可用于本发明的水溶性聚合胶凝剂选自合成的或天然的聚合物、以及它们的混合物。通常,本发明的预成形凝胶片包含按总重量计少于50%,更优选少于30%和尤其少于20%的水溶性聚合胶凝剂。适用于本文的合成聚合物包括非离子水溶性聚合物、丙烯酸基聚合物、纤维素衍生物、以及它们的混合物。
尤其优选的合成聚合物体系公开于引入本文以供参考的WO00/06215,其描述了适于将生物医学装置连接到皮肤上的产品。具体地讲,该文献公开了生物粘附的水凝胶组合物,该组合物包含含水增塑剂、一种或多种单体的聚合物(该单体包含亲水的不饱和水溶性丙烯酰胺单体尤其是NaAMPS)、和疏水聚合物例如乙烯/乙酸乙烯酯共聚物。
物理交联是指聚合物具有不是化学共价键而是物理性质的交联,以致存在具有高结晶度的区域或具有高玻璃化转变温度的区域。也可使用这些交联聚合物。优选地,聚合物是化学热交联的。另外当在体系中形成化学交联时,多官能的交联剂和/或自由基引发剂可以存在于预混物中以便在照射后引发交联。
优选地,本文的预成形水凝胶包括天然来源的水溶性聚合胶凝剂的混合物。本文优选的水溶性聚合胶凝剂混合物可以包含多糖和非离子水溶性聚合物,或可供选择地可以包含两种多糖。更优选地,水溶性聚合物凝胶形成剂是多糖混合物,其中多糖混合物包含(1)至少一种红海藻多糖、褐海藻多糖或它们的混合物;和(2)至少一种发酵多糖、半乳甘露聚糖、葡甘露聚糖、天然植物渗出物,或天然果实提取物,以及它们的衍生物或混合物。甚至更优选地,本发明预成形水凝胶的水溶性聚合物凝胶形成剂是多糖混合物,其包含(1)至少一种红海藻多糖;和(2)至少一种发酵多糖、葡甘露聚糖或半乳甘露聚糖、以及它们的衍生物或混合物。
在一个提供不含支持性基质的预成形水凝胶的优选实施方案中,本发明的水溶性聚合凝胶形成剂是多糖混合物,其包含红海藻多糖和葡甘露聚糖或半乳甘露聚糖。多糖混合物中的红海藻多糖与葡甘露聚糖或半乳甘露聚糖的比率优选为约20∶1至约1∶5,更优选约10∶1至约1∶2。不受理论的约束,据信本文的凝胶组合物形成结合或胶囊包封组合物其它成分的三维网络或基体。
溶剂
本发明的预成形水凝胶包括用于胶凝剂的溶剂,该溶剂可为水、水溶液或水分散体。典型地,为了最终提供均匀的单层预成形水凝胶,胶凝剂至少在溶胶相状态下可混溶于溶剂中。根据所需的机械性质,尤其是凝胶强度和柔韧性,还根据所得产品的所需特性,确定溶剂的数量和种类以提供具有胶凝剂的稳定凝胶相。优选地,溶剂还作为预成形水凝胶的增塑剂或软化剂。
对于局部应用,预成形水凝胶包含亲水溶剂。本文提到溶剂时所用术语“亲水的”是指溶剂可与水混合,溶剂和水的比率为至少1比10,优选1比5。局部可用的亲水溶剂是可用于施用于皮肤的预成形水凝胶中而不会引起刺激并且可与水混溶的那些。合适的亲水溶剂包括低级醇如乙醇,和多元醇如丙二醇、丁二醇、己二醇、甘油、山梨醇、MW小于30,000,优选小于10,000的聚乙二醇、和MW小于5,000,优选小于1,000的聚丙二醇。有利的是,许多作为亲水溶剂用于本文的多元醇还对皮肤起到湿润剂的作用。此外,亲水溶剂可帮助皮肤有益剂扩散进皮肤,并通过从预成形水凝胶蒸发,还可以提供冷却,使预成形水凝胶的使用更舒适。在后者方面,优选25℃时是液体的溶剂。对于局部应用,优选地溶剂包括水和至少一种多元醇,更优选地溶剂基本上由水和多元醇组成。在一个优选实施方案中,所述预成形水凝胶包含约10%至约99.5%,更优选约20%至约95%,还更优选约30%至约90%的水。还优选地,所述预成形水凝胶还包含约1.0%至约50%,优选约5%至约45%,更优选约10%至约40%的多元醇。
对于口服使用,溶剂选自上述对于口服应用是安全的和优选可口的一组物质。
有益组分
本发明的装置包含有益组分。当在使用中接触时,本发明的有益组分可向预成形水凝胶组分提供附加有益效果,然而该有益组分包含至少一种当与预成形水凝胶组分接触时不稳定的化合物。因此,最终水凝胶产品要即用即制。有益组分可为液体、粉末或固体形式,优选为液体或粉末。有益组分可包含这样的化合物,当其与预成形水凝胶组分接触时可增强脱水收缩作用、提高硬度或产生不美观的颜色、味道、风味和/或气味。有益组分可包含临时化合物或催化剂,其与包含在预成形水凝胶组分中的水反应。有益组分可包含这样的化合物,其通过容易溶解/吸收在预成形水凝胶组分中,或者从预成形水凝胶组分中吸收溶剂,而快速改变其物理属性或降低其性能。
已知与预成形水凝胶组分尤其是与水不稳定,因此适于包含在有益组分中的化合物是,例如易氧化的水溶性化合物、产热化合物、粉末化合物、荷电化合物、气体形成化合物、以及它们的混合物。本文的不稳定化合物可通过其化学/物理性质或其假定的作用模式来分类或描述。然而应当理解,本文的不稳定化合物有时候能提供多于一种的有益效果或通过多于一种的作用方式起作用。因此,本文的分类只是为了方便,并非旨在将化合物限制在特别指出的特性内。
本文易氧化的水溶性化合物包括抗坏血酸。尽管抗坏血酸化合物可用于局部应用和口服,但当接触超过约5天后它们会向预成形水凝胶提供明显的黄色。当抗坏血酸化合物局部应用时可提供亮肤有益效果,并且当口服时可提供有特色的风味。可用于本发明的抗坏血酸化合物包括本身为L-型的抗坏血酸、抗坏血酸盐、以及它们的衍生物。可用于本发明的抗坏血酸的盐包括钠盐、钾盐、锂盐、钙盐、镁盐、钡盐、铵盐和精蛋白盐。可用于本发明的抗坏血酸衍生物包括例如抗坏血酸的酯和抗坏血酸的酯盐。尤其优选的抗坏血酸化合物包括2-o-D-吡喃葡萄糖基-L-抗坏血酸(其为抗坏血酸和葡萄糖的酯,且通常称为L-抗坏血酸2-葡糖苷,或抗坏血酸基葡糖苷)及其金属盐,和L-抗坏血酸磷酸酯盐(如抗坏血酸磷酸钠、抗坏血酸磷酸钾、抗坏血酸磷酸镁和抗坏血酸磷酸钙)。市售的抗坏血酸化合物包括购自showa Denko的抗坏血酸磷酸镁、购自Hayashibara的2-o-D-吡喃葡萄糖基-L-抗坏血酸和以商品名STAY C购自Roche的L-抗坏血酸磷酸钠。
本文的产热化合物包括当打破密封进行制备时与大量空气接触和/或与包括在水凝胶组分中的水接触产生热量的那些。当局部应用时热量的产生可提供令人愉悦的温暖感,并且还可增强包括在水凝胶组分和/或有益组分内的活性成分的渗透。合适的产热化合物包括,例如,氯化物如氯化钙(CaCl2、CaCl2·H2O、CaCl2·2H2O)、氯化镁(MgCl2、MgCl2·2H2O、MgCl2·4H2O)、氯化铝(AlCl3、AlCl3·6H2O)、氯化铁(FeCl3、FeCl3·2H2O)和氯化锌(ZnCl2);硫酸盐如硫酸镁(MgSO4、MgSO4·H2O、MgSO4·4H2O)、硫酸锌(ZnSO4·H2O)、硫酸亚铁(FeSO4、FeSO4·H2O)、硫酸铝(Al(SO4)3)、硫酸钙(CaSO4、CaSO4·1/2H2O、CaSO4·H2O)和硫酸钠(Na2SO4);干燥明矾;氧化钙(CaO);氧化镁(MgO);碳酸钠(Na2CO3);氧化铁;氧化锌;沸石;和磷酸氢二钠(Na2HPO4)。根据其产生热量的有效性、对毛发和/或皮肤的温和性及易处理性,优选的是无水无机盐如硫酸钠(Na2SO4)、硫酸钙(CaSO4)、硫酸镁(MgSO4)、硫酸铝(Al(SO4)3)、氯化钙(CaCl2)、氯化镁(MgCl2)、氧化钙(CaO)、以及它们的混合物。更优选的是无水硫酸镁(MgSO4)。根据处理时或者当局部施用时防止粗糙感,可用于本发明的产热化合物具有优选约0.01μm至约40μm,更优选约0.05μm至约30μm,还更优选约0.1μm至约20μm的平均直径。
本文的粉末化合物典型地通过容易溶解/吸收在预成形水凝胶组分中,或者从预成形水凝胶组分中吸收溶剂,而快速改变其物理属性或降低其性能。粉末化合物可为提供局部有益效果或利于口服的任何该化合物。本文局部应用的粉末化合物包括提供有特色的皮肤感觉的那些,例如二氧化钛、滑石、纤维素粉、氧化铁、硅氧烷树脂、氧化铁、氧化锌等等。本文的口服粉末化合物包括,例如盐、糖、胡椒粉、米粉、纤维素粉、淀粉、可可粉、大豆粉、面粉等等。
荷电化合物如电解质和离子表面活性剂是用于去污目的的有用化合物,然而当接触时,其可增强脱水收缩作用或甚至分解预成形水凝胶。本文的荷电化合物包括例如任何提供碱金属或碱土金属离子的电解质、阴离子表面活性剂、阳离子表面活性剂、阴离子聚合物、阳离子聚合物等等。
可用于本发明的气体形成化合物是当与溶剂,典型地与水接触时提供任何种类的泡腾剂效果的那些。气体形成化合物可适于任何产品以提供最终产品产生的视觉、听觉或嗅觉信号。气体形成化合物可增强味道和风味,增强局部吸收或增强去污效果。可用于本发明的气体形成化合物是溶解于水中时产生二氧化碳的碱性盐,包括碳酸钠、碳酸氢钠、倍半碳酸钠、碳酸钾、碳酸氢钾、倍半碳酸钾、以及它们的混合物。当使用此类碱性盐时,还包含有机酸或其盐以调节最终水凝胶产品的pH是优选的。用于该用途的合适有机酸包括脂族羧酸如柠檬酸、酒石酸、苹果酸、草酸、丙二酸、琥珀酸、戊二酸、己二酸、富马酸和马来酸,芳族羧酸如苯甲酸、邻苯二甲酸、间苯二甲酸、对苯二甲酸、和肉桂酸,杂环羧酸如烟酸、酸性氨基酸如谷氨酸和天冬氨酸、以及它们的混合物。还可用于本发明的是包含捕集在所述颗粒内的加压气体的颗粒。
局部应用产品
在一个高度优选的实施方案中,本发明的最终预成形水凝胶产品是用于将皮肤有益剂递送到皮肤、毛发或指甲的片状贴剂。该产品的尺寸通常使得每个表面具有约0.25cm2至约1,000cm2,优选约1cm2至约400cm2的面积。表面积是指具有与该表面具有相同边界的平坦平面的表面积,即忽略任何存在的表面纹理。本文预成形水凝胶可以是,例如,正方形、圆形、半圆形、矩形、椭圆形、环形、月牙形、泪珠状或其它由这些形状复合的更复杂的形状,用于覆盖如眼部区域、眼睑、鼻子、嘴部区域、前额、面颊、下巴、脸部整个轮廓、颈部、胳膊、身体的其它具体位置,或它们的组合。所述预成形水凝胶应当是足以柔韧的以沿着其施用的皮肤表面贴合。但是,需要最小的凝胶强度,从而当悬垂时(例如当使用者使用该产品时)预成形水凝胶在其自身重量下不破裂。
本发明还涉及最终预成形水凝胶产品,该产品包含:
(1)预成形水凝胶组分,其包含:
(a)约10%至约99.5%的水;和
(b)约0.5%至约20%的多糖胶凝剂;
其中该预成形水凝胶组分不含支持性基质,厚度为约0.1mm至约5mm,优选约0.5mm至约2.0mm,并且具有第一表面和第二表面,第一表面具有深度为约10μm至约500μm,优选约50μm至约200μm,频率为每毫米约0.2至约1,优选每毫米约0.3至约0.7个的重复纹理;其中纹理的深度为预成形水凝胶组分厚度的至少约10%;和
(2)包含皮肤有益剂的有益组分,并且粘度为约1000mPa·s至约100,000mPa·s,优选为约5000mPa·s至约300,000mPa·s;
其中所述重复纹理这样设计以提供槽的网络,该网络容许当第一表面应用到皮肤上时有益组分的流体连通。
本文所用术语“第一表面”是指应用到皮肤上的预成形水凝胶的表面,并且当其包装在第一隔室内时面向密封。
本文所用术语“厚度”是指预成形水凝胶组分的厚度,其中当片有纹理时,纹理的最高点用于测量厚度。
本文所用术语“深度”涉及预成形水凝胶组分表面上所提供纹理的厚度方向上的长度。
本文所用术语“频率”涉及每毫米上非平面外形的重复数量,为预成形片的表面提供纹理的非平面外形的重复。
本发明的预成形水凝胶组分具有一定的厚度和第一表面一定深度和频率的纹理,向使用者提供多种有益效果。当包装在第一隔室内时,第一表面面向密封放置,从而当将预成形水凝胶组分转移到第二隔室内时,第一表面直接与有益组分接触,因此使用者可将此表面施用在皮肤上。在一个高度优选的实施方案中,有益组分的含量和粘度使得其仅仅覆盖预成形水凝胶的第一表面,如图5中所描述。
最终的预成形水凝胶产品包含有益组分,该组分通过将第一表面施用到皮肤上而有利于产品方便附着到皮肤上。该水凝胶产品应用到皮肤上后,有益组分立即均匀分布在应用该产品的整个区域,为不连续的、隔开的使用者接触区域留下或多或少的真空。因此,该产品被吸附到皮肤上。为了该产品在皮肤上的此类有效吸附,预成形水凝胶组分优选在厚度上是均匀的。槽还在预成形水凝胶组分和皮肤之间提供有益组分的贮存器,因此容许有益组分与皮肤的连续接触。具有上述尺寸的水凝胶产品可提供对皮肤的足够附着,使得即使当以垂直方式应用时,该产品也不容易被拉下皮肤。
有益组分可为水溶液,包括凝胶,或乳液例如水包油乳液、油包水乳液或具有水或油外部相的多相乳液,所有这些的粘度介于约1000mPa·s和约100,000mPa·s之间。涂层组合物的粘度使用heliopath T-连接杆C转轴以0.5rad/s(5rpm)在Brookfield粘度计上测得。
有益组分对预成形水凝胶组分的重量比通常大于约1∶50,优选约1∶25,更优选约1∶15至约10∶1。
本文的预成形水凝胶组分可通过任何合适的方法制备,优选通过利用胶凝剂的凝胶转变点的冷却方法。其它方法包括喷射模塑法。
在一个高度优选的实施方案中,有益组分包含安全有效量的,优选约0.1%至约10%的抗坏血酸化合物,以向皮肤提供长期亮肤有益效果。
皮肤有益剂
在一个高度优选的实施方案中,有益组分是包含至少一种用于皮肤、毛发或指甲的皮肤有益剂的液体组合物。优选地,预成形水凝胶组分和有益组分各自包含至少一种共同的皮肤有益剂。对本发明而言,在本文这个部分讨论的皮肤有益剂不包括与预成形水凝胶组分不稳定的那些化合物。
当包括常见的皮肤有益剂时,有益组分在使用时能够向目标区域迅速提供皮肤有益剂,同时预成形水凝胶可作为皮肤有益剂的贮存器或者抑制预成形水凝胶从有益组分中吸收皮肤有益剂。
本文所用术语“皮肤有益剂”是指为皮肤、毛发或指甲上的应用区域提供化妆品和/或治疗效果的活性成分。可用于本发明的皮肤有益剂包括抗痤疮剂、润肤剂、非甾族抗炎剂、局部麻醉剂、人工晒黑剂、防腐剂、抗微生物的和抗真菌活性物质、皮肤抚慰剂、防晒剂、皮肤阻挡层修复剂、抗皱剂、抗皮肤萎缩活性物质、类脂、亮肤剂、皮脂抑制剂、皮脂抑制剂、皮肤增感剂、蛋白酶抑制剂、紧肤剂、抗痒剂、毛发生长抑制剂、脱屑酶增强剂、抗糖化作用剂、以及它们的混合物。
优选地,本发明的有益组分包含按所述有益组分的重量计约0.01%至约60%,优选约0.1%至约40%,最优选约0.5%至约30%的至少一种皮肤有益剂或它们的混合物。
可用于本发明的皮肤有益剂的优选实施例包括选自以下的那些:水杨酸、烟酰胺、泛醇、生育酚烟酸盐、过氧化苯甲酰、3-羟基苯甲酸、类黄酮(例如,黄烷酮、查耳酮)、金合欢醇、植烷三醇、乙醇酸、乳酸、4-羟基苯甲酸、乙酰基水杨酸、2-羟基丁酸、2-羟基戊酸、2-羟基己酸、顺式-视黄酸、反式-视黄酸、视黄醇、视黄基酯(例如视黄基丙酸酯)、植酸、N-乙酰基-L-半胱氨酸、硫辛酸、生育酚及其酯(例如生育酚乙酸酯)、壬二酸、花生四烯酸、四环素、布洛芬、萘普生、酮洛芬、氢化可的松、扑热息痛、间苯二酚、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、2,4,4′-三氯-2′-羟基二苯醚、3,4,4′-三氯碳酰苯胺、羟甲辛吡酮、利多卡因盐酸盐、克霉唑、咪康唑、酮康唑、硫酸新霉素、茶碱、以及它们的混合物。
对于皮肤、毛发或指甲处理的化妆方法,化妆用皮肤有益剂优选选自抗皱剂和抗皮肤萎缩活性物质、抗痤疮活性物质、人工晒黑剂和促进剂、润肤剂、湿润剂、皮肤修复活性物质、皮肤障碍物修复助剂、亮肤剂、皮肤增感剂、皮肤抚慰剂、类脂、皮脂抑制剂、皮脂刺激剂、防晒剂、蛋白酶抑制剂、紧肤剂、抗痒剂成分、和脱屑酶增强剂或它们的混合物。
本文预成形水凝胶组分和有益组分的pH优选为约3至约9,更优选约4至约8。根据皮肤有益剂的活性选择pH。
依据本文所包含的皮肤有益剂,本发明的最终预成形水凝胶产品可以具有至少一种下列用途:为皮肤、毛发或指甲补充水分;平滑细纹和皱纹;美容处理痤疮;紧肤或软化皮肤;强化、软化、脱落、改善和/或匀化肤色和/或皮肤肌理;增亮皮肤、毛发或指甲;使皮肤成褐色;减小毛孔出现;吸收或控制分泌物;保护和/或抚慰皮肤、毛发或指甲、肌肉、疼痛或伤痛;减轻浮肿和/或黑圈;刺激创伤愈合;使皮肤、毛发或指甲升温、清新或冷却;消炎;增亮肤色;减轻充血;减轻肿胀;治疗皮肤病症;增加弹性;净化;香化;减少细菌或微生物生长;愈合;驱虫;去除多余毛发、污垢或化妆;和使涂敷最终预成形水凝胶产品的目标区域染色或漂白。
使用方法
依照上述的制备步骤,本发明的最终水凝胶产品在应用到皮肤上之前立即制备,优选在应用前约10分钟内制备。将最终水凝胶产品的第一表面应用到皮肤上,使得表面纹理提供的槽网络容许有益组分的流体连通。将这样获得的最终水凝胶产品施用于皮肤、毛发或指甲的目标区域,并且通常将留在目标区域约1分钟至约12小时,优选约5至约60分钟。
实施例
下列实施例进一步描述和说明了在本发明范围内的优选实施方案。给出这些实施例仅仅是为了说明本发明,不可解释为是对本发明的限制,因此在不背离本发明精神和范围的条件下,可以对其进行许多改变。
即用即制装置是由具有下列组合物的组分制成,并通过本文所述的方法形成:
表1-用于水凝胶组分的组合物1至6
为提供成形结构,实施例4至6还包括支持层。
表2-用于有益组分的组合物7至11
表3-用于有益组分的组合物12
成分(重量百分比) | 实施例12 |
烟酰胺 | 3.5 |
云母 | 45.0 |
二氧化钛 | 7.0 |
二氧化铁 | 1.5 |
角鲨烷 | 5.0 |
异辛酸鲸蜡酯 | 3.0 |
异辛酸甘油酯 | 7.0 |
滑石 | 至100% |
1Kelgum和Keltrol T分别是黄原胶和刺槐豆胶的1∶1混合物,且黄原胶由Kelco,San Diego,CA,USA供应。
2聚甲基倍半硅氧烷,得自Toshiba
3聚二甲基硅氧烷、聚二甲基硅氧烷醇、月桂基聚氧乙烯醚-4、月桂基聚氧乙烯醚-23和水,得自Dow Corning
4水和鲸蜡基甜菜碱,得自Lonza
5水、生育酚乙酸酯、聚山梨酸酯80、辛酸/癸酸甘油三酯和卵磷脂,得自CIBA
6Arlatone 2121,得自ICI
7NaAMPS,得自Lubrizol
8Darocure PI,得自Ciba Geigy
9IRR 210XL,得自UCB chemicals
10酵母发酵滤液:SKII Pitera,购自Kashiwayama
装置的制备
本文的即用即制装置可通过本领域已知的任何合适的方法制造。实施例1至6的水凝胶组分可与实施例7至12的任何有益组分结合以提供局部应用产品。包括实施例7至11作为有益组分的产品尤其适用于护肤产品。包括实施例12作为有益组分的产品尤其适于作为粉底产品。
优选地,本装置可通过连续生产线制造,其中预成形水凝胶组分的制备包括以下步骤:
(1)提供预成形水凝胶组分的溶胶相组合物,其被加热至高于溶胶-凝胶转变点至少5℃的温度;
(2)将所述溶胶相组合物预冷却至比所述溶胶-凝胶转变点高0℃至5℃的温度;
(3)通过在两个衬料之间挤压所述溶胶相组合物形成表面,这两个衬料可通过两个彼此相对的反转辊提供,其中所述辊还包括冷却部件;
(4)通过冷却至不高于20℃将溶胶相组合物冷却至凝胶相内;和
(5)用冲模切割凝胶相组合物。
提供由聚丙烯制备的具有图3所示构型的包装和由铝层压材料制成的密封部件,其中聚对苯二甲酸乙二醇酯在外侧而聚丙烯在内侧。
如上所得的预成形水凝胶组分还可被转移到提供本装置的方法中,所述方法包括以下步骤:
(6)提供一连串未密封的包装,每个包装单元具有第一隔室和第二隔室;
(7)将有益组分施用在包装的第二隔室内;
(8)将预成形水凝胶组分放置在包装的第一隔室内;
(9)密封包装;
(10)在包装材料内提供凹口以分开第一隔室和第二隔室;和
(11)提供穿孔以分开每个单元装置。
即用即制最终产品
通过打开密封、在凹口处折叠包装、并将预成形水凝胶组分转移到第二隔室内以接触有益组分得到最终预成形水凝胶产品。
将如此所得的产品施用于皮肤的目标区域。
当由任何一个实施例1至3与任何一个实施例7至11组合制成的产品一天两次施用于面部皮肤时,每次施用至少15分钟,且使用至少2周,可提供长期亮肤有益效果。此类产品还可提供皱纹/细纹的减少、肌理改善和皮肤保湿效果。
应当理解,虽然仅通过举例说明的方式给出了本发明实施例和实施方案的上述详细描述,但是对于本领域的技术人员显而易见的是,在不背离本发明精神和范围的情况下可进行各种改变和改进,并且这种明显的改变和改进都包括在所附的权利要求范围内。
在发明详述中引用的所有文献的相关部分均引入本文以供参考;任何文献的引用并不可理解为是对其作为本发明的现有技术的认可。
尽管已用具体实施方案来说明和描述了本发明,但对于本领域的技术人员显而易见的是,在不背离本发明的精神和保护范围的情况下可作出许多其它的变化和修改。因此,有意识地在附加的权利要求书中包括本发明范围内的所有这些变化和修改。
Claims (9)
1. 一种即用即制装置,所述装置包含:
(1)包装在第一隔室内的预成形水凝胶组分;所述预成形水凝胶组分包含胶凝剂和溶剂;和
(2)包装在第二隔室内的有益组分;所述有益组分包含至少一种化合物,所述化合物在与所述预成形水凝胶组分接触时不稳定;
其中所述第一和第二隔室在使用前分别包装,并且其中所述装置包括在使用时接触预成形水凝胶组分和有益组分的部件。
2. 如权利要求1所述的装置,其中所述有益组分包含化合物,所述化合物选自易氧化的水溶性化合物、产热化合物、粉末化合物、荷电化合物、气体形成化合物以及它们的混合物。
3. 如权利要求1所述的装置,其中所述接触部件是位于所述第一和第二隔室之间的凹口区域;所述凹口区域具有一定强度,使得其可被使用者折叠而不会完全破裂。
4. 如权利要求3所述的装置,其中所述预成形水凝胶组分被转移至第二隔室内进行制备。
5. 如权利要求1所述的装置,其中所述第一隔室在内表面上具有压花以利于释放所述预成形水凝胶组分,并且其中所述第二隔室在内表面上具有压花以利于在使用时制备所述最终产品。
6. 如权利要求1所述的装置,用于局部应用,其中所述有益组分包含抗坏血酸化合物。
7. 如权利要求1所述的装置,用于局部应用,其中所述有益组分包含产热化合物。
8. 如权利要求1、6或7中任一项所述的装置,用于局部应用,其中:
(1)所述预成形水凝胶组分包含:
(a)10%至99.5%的水;和
(b)0.5%至20%的多糖胶凝剂;
其中所述预成形水凝胶组分不含支持性基质;和
(2)其中所述有益组分包含抗坏血酸化合物。
9. 如权利要求1、6或7中任一项所述的装置,用于局部应用,其中:
(1)所述预成形水凝胶组分包含:
(a)10%至99.5%的水;和
(b)0.5%至20%的多糖胶凝剂;
其中所述预成形水凝胶组分不含支持性基质,具有0.1mm至5mm的厚度以及第一表面和第二表面,所述第一表面具有深度为10μm至500μm且频率为每毫米0.2至1个的重复纹理,其中所述纹理的深度为所述预成形水凝胶组分厚度的至少10%;和
(2)其中所述有益组分包含抗坏血酸化合物和皮肤有益剂,且粘度为1000mPa·s至100,000mPa·s;
其中所述重复纹理设计成提供槽网络,所述槽网络容许当所述第一表面在与所述有益组分接触之后被应用到皮肤上时所述有益组分的流体连通。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47754603P | 2003-06-11 | 2003-06-11 | |
US60/477,546 | 2003-06-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1805736A CN1805736A (zh) | 2006-07-19 |
CN100418516C true CN100418516C (zh) | 2008-09-17 |
Family
ID=33551729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004800161900A Expired - Lifetime CN100418516C (zh) | 2003-06-11 | 2004-06-07 | 包括预成形水凝胶产品的即用即制装置 |
Country Status (10)
Country | Link |
---|---|
US (3) | US7854938B2 (zh) |
EP (1) | EP1633332A1 (zh) |
JP (1) | JP4223531B2 (zh) |
KR (1) | KR100738264B1 (zh) |
CN (1) | CN100418516C (zh) |
AU (1) | AU2004247102A1 (zh) |
BR (1) | BRPI0411333A (zh) |
CA (1) | CA2525786A1 (zh) |
MX (1) | MXPA05013213A (zh) |
WO (1) | WO2004110414A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109689011A (zh) * | 2016-10-04 | 2019-04-26 | 竹原隆 | 氢产生式面膜片 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007142054A1 (ja) | 2006-06-06 | 2007-12-13 | Taiki Corp., Ltd. | シース状塗布具及びその製造方法 |
DE102006028384A1 (de) * | 2006-06-19 | 2007-12-20 | Beiersdorf Ag | Kombinationsset zur dekorativen Pflege der Haut |
KR101179900B1 (ko) * | 2006-07-14 | 2012-09-06 | 더 프록터 앤드 갬블 캄파니 | 집중 케어와 총체적 트리트먼트를 동시에 전달할 수 있는 트리트먼트 용품 |
US20080241200A1 (en) * | 2007-03-30 | 2008-10-02 | Marcy Elizabeth Sojka | Cosmetic skin care system |
DE102007039229A1 (de) * | 2007-08-20 | 2009-02-26 | Ics Innovative Care Systems Andernach Gmbh | Wasser- und wirkstoffhaltiges Gel |
FR2940111B1 (fr) * | 2008-12-19 | 2012-06-01 | Oreal | Kit de revetement des matieres keratiniques comprenant un polysaccharide et un agent de complexation ionique ou dative |
FR2940115B1 (fr) * | 2008-12-19 | 2012-06-15 | Oreal | Kit de revetement des matieres keratiniques comprenant un polysaccharide et un agent de reticulation chimique |
FR2955252B1 (fr) * | 2010-01-21 | 2012-03-23 | Patrick Lesage | Materiau d'insertion destine a elargir le sillon gingival |
JP2012092022A (ja) * | 2010-10-25 | 2012-05-17 | Tokuhon Corp | 皮膚外用貼付剤 |
KR101951916B1 (ko) * | 2011-03-31 | 2019-02-25 | 닛산 가가쿠 가부시키가이샤 | 화장료의 제조방법, 화장료용 겔의 조제방법 및 화장료 원료에 배합되는 고분자 증점제의 사용량을 경감하는 방법 |
US20120283668A1 (en) * | 2011-05-04 | 2012-11-08 | Pinchas Shalev | Apparatus and method for using effervescent tablets for cosmetic care |
PT106679B (pt) | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | Formulações tópicas de tetraciclinas, sua preparação e usos |
BR112015024772A2 (pt) * | 2013-04-10 | 2017-07-18 | Procter & Gamble | composições para tratamento bucal contendo partículas de poli-organossilsesquioxano |
AU2014250971B2 (en) | 2013-04-10 | 2016-07-21 | The Procter & Gamble Company | Oral care compositions containing polyorganosilsesquioxane particles |
EP2983635A1 (en) | 2013-04-10 | 2016-02-17 | The Procter & Gamble Company | Oral care compositions containing polyorganosilsesquioxane particles |
US20170042311A1 (en) | 2014-10-21 | 2017-02-16 | The Procter & Gamble Company | Method of Improving Skin Appearance |
KR102481341B1 (ko) | 2014-10-31 | 2022-12-23 | 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 | 피부 표면으로 활성 작용제의 전달을 위한 열가소성 폴리우레탄 필름 |
US20160200500A1 (en) * | 2015-01-07 | 2016-07-14 | Lavico Inc. | L-Ascorbic Acid Formulations and Methods of Use for Skin Care |
GB2543495B (en) * | 2015-10-16 | 2019-06-12 | Gr8 Eng Ltd | Container with frangible weakened portion and manufacture thereof |
US10537498B2 (en) | 2015-10-22 | 2020-01-21 | The Procter & Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
EP3365066B1 (en) | 2015-10-22 | 2019-11-20 | The Procter and Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
EP3393447B1 (en) * | 2015-12-25 | 2023-08-30 | Henkel AG & Co. KGaA | A sprayable gel composition and use thereof |
FR3053247B1 (fr) * | 2016-07-01 | 2020-04-24 | L'oreal | Procede cosmetique de traitement des matieres keratiniques mettant en œuvre une composition comprenant de l’acide ascorbique |
US10751265B2 (en) | 2017-01-09 | 2020-08-25 | The Procter & Gamble | Barrier patch with soluble film and methods of improving skin appearance |
EP3565642A1 (en) | 2017-01-09 | 2019-11-13 | The Procter and Gamble Company | Barrier patch with soluble film and methods of improving skin appearance |
US10857076B2 (en) | 2017-01-09 | 2020-12-08 | The Procter & Gamble Company | Barrier patch with soluble film and methods of improving skin appearance |
CN110769945B (zh) | 2017-06-22 | 2023-01-24 | 宝洁公司 | 包括水溶性层和气相沉积涂层的美容护理品膜 |
KR101891514B1 (ko) * | 2017-09-25 | 2018-09-28 | (주)아모레퍼시픽 | 하이드로겔을 이용한 피부 미용 팩 제조 장치 및 그 제어 방법 |
DE102018203223A1 (de) * | 2018-03-05 | 2019-09-05 | Beiersdorf Ag | Fruchtsäure-haltiges, kosmetisches Gel |
EP3768249B1 (en) | 2018-03-19 | 2024-04-17 | The Procter & Gamble Company | Method of making a barrier patch with soluble film |
US10918514B2 (en) * | 2018-08-12 | 2021-02-16 | Eric Vélez Justiniano | Tamper evident packaging |
US11135336B2 (en) | 2019-09-30 | 2021-10-05 | L'oreal | Thin-film vehicles that stabilize highly reactive active ingredients |
FR3127878B1 (fr) * | 2021-10-12 | 2024-04-05 | Oreal | compositions de traitement des cheveux apportant luminosité et brillance |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4927408A (en) * | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
US5084008A (en) * | 1989-12-22 | 1992-01-28 | Medtronic, Inc. | Iontophoresis electrode |
US5651979A (en) * | 1995-03-30 | 1997-07-29 | Gel Sciences, Inc. | Apparatus and method for delivering a biologically active compound into a biological environment |
US5882677A (en) * | 1997-09-30 | 1999-03-16 | Becton Dickinson And Company | Iontophoretic patch with hydrogel reservoir |
US20010007671A1 (en) * | 1998-07-30 | 2001-07-12 | L'oreal | Cosmetic, pharmaceutical, or dermatological patch |
US6510561B1 (en) * | 1998-10-21 | 2003-01-28 | Reckitt Benckiser (Uk) Limited | Dispensing device |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US76711A (en) * | 1868-04-14 | Improvement in shifting-bucket propellers | ||
JPH06336413A (ja) | 1993-03-31 | 1994-12-06 | Shiseido Co Ltd | 発熱パック化粧料 |
US5393305A (en) * | 1993-08-26 | 1995-02-28 | Bristol-Myers Squibb Company | Two-part aqueous composition for coloring hair, which forms a gel on mixing of the two parts |
FR2718018B1 (fr) * | 1994-04-05 | 1996-04-26 | Oreal | Composition cosmétique et/ou dermatologique à support hydrophile et vitamine C mélangeables extemporanément. |
US5984953A (en) * | 1998-05-21 | 1999-11-16 | Tempra Technology, Inc. | Self-regulating heat pack |
FR2781670B1 (fr) * | 1998-07-30 | 2001-09-07 | Oreal | Patch cosmetique ou pharmaceutique et son conditionnement |
DE29814215U1 (de) | 1998-08-12 | 1998-10-15 | Klocke Verpackungs-Service GmbH, 76356 Weingarten | Mehrkammerbehälter |
US6138312A (en) * | 1999-03-26 | 2000-10-31 | Cummings; Eugene M. | Single-use contact lens treatment apparatus |
JP2000297008A (ja) | 1999-04-12 | 2000-10-24 | Pola Chem Ind Inc | 発泡性化粧料 |
US7658942B2 (en) * | 2000-04-12 | 2010-02-09 | The Procter & Gamble Company | Cosmetic devices |
CA2402791C (en) | 2000-04-12 | 2007-06-26 | The Procter & Gamble Company | Pre-formed sheet devices for topical application comprising a benefit agent coated solid gel sheet |
CN1273118C (zh) * | 2001-12-11 | 2006-09-06 | 宝洁公司 | 制造预成形物品的方法 |
-
2004
- 2004-06-07 CA CA002525786A patent/CA2525786A1/en not_active Abandoned
- 2004-06-07 BR BRPI0411333-0A patent/BRPI0411333A/pt not_active Application Discontinuation
- 2004-06-07 EP EP04754556A patent/EP1633332A1/en not_active Withdrawn
- 2004-06-07 CN CNB2004800161900A patent/CN100418516C/zh not_active Expired - Lifetime
- 2004-06-07 AU AU2004247102A patent/AU2004247102A1/en not_active Abandoned
- 2004-06-07 MX MXPA05013213A patent/MXPA05013213A/es unknown
- 2004-06-07 KR KR1020057023662A patent/KR100738264B1/ko active IP Right Grant
- 2004-06-07 WO PCT/US2004/017985 patent/WO2004110414A1/en active Application Filing
- 2004-06-07 JP JP2006533583A patent/JP4223531B2/ja not_active Expired - Lifetime
- 2004-06-09 US US10/864,564 patent/US7854938B2/en not_active Expired - Fee Related
-
2010
- 2010-11-11 US US12/944,047 patent/US8066117B2/en not_active Expired - Fee Related
-
2011
- 2011-10-27 US US13/282,568 patent/US8353399B2/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4927408A (en) * | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
US5084008A (en) * | 1989-12-22 | 1992-01-28 | Medtronic, Inc. | Iontophoresis electrode |
US5651979A (en) * | 1995-03-30 | 1997-07-29 | Gel Sciences, Inc. | Apparatus and method for delivering a biologically active compound into a biological environment |
US5935593A (en) * | 1995-06-07 | 1999-08-10 | Medlogic Global Corporation | Chemo-mechanical expansion delivery system |
US5882677A (en) * | 1997-09-30 | 1999-03-16 | Becton Dickinson And Company | Iontophoretic patch with hydrogel reservoir |
US20010007671A1 (en) * | 1998-07-30 | 2001-07-12 | L'oreal | Cosmetic, pharmaceutical, or dermatological patch |
US6510561B1 (en) * | 1998-10-21 | 2003-01-28 | Reckitt Benckiser (Uk) Limited | Dispensing device |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109689011A (zh) * | 2016-10-04 | 2019-04-26 | 竹原隆 | 氢产生式面膜片 |
Also Published As
Publication number | Publication date |
---|---|
US8066117B2 (en) | 2011-11-29 |
KR100738264B1 (ko) | 2007-07-12 |
EP1633332A1 (en) | 2006-03-15 |
AU2004247102A1 (en) | 2004-12-23 |
KR20060016807A (ko) | 2006-02-22 |
MXPA05013213A (es) | 2006-03-09 |
JP4223531B2 (ja) | 2009-02-12 |
JP2007501286A (ja) | 2007-01-25 |
US20040253313A1 (en) | 2004-12-16 |
US20110056943A1 (en) | 2011-03-10 |
US8353399B2 (en) | 2013-01-15 |
BRPI0411333A (pt) | 2006-07-25 |
WO2004110414A1 (en) | 2004-12-23 |
US20120041396A1 (en) | 2012-02-16 |
CN1805736A (zh) | 2006-07-19 |
US7854938B2 (en) | 2010-12-21 |
CA2525786A1 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100418516C (zh) | 包括预成形水凝胶产品的即用即制装置 | |
JP4157840B2 (ja) | 予備成形物の作製プロセス | |
US7658942B2 (en) | Cosmetic devices | |
CN1289059C (zh) | 适于局部涂敷的预成型薄片器件 | |
CN1988882A (zh) | 基于基底的护肤制品 | |
AU2000242314A1 (en) | Pre-formed sheet devices suitable for topical application | |
US20060198805A1 (en) | Cosmetic and Pharmaceutical Masks for Skin Improvement | |
KR20190058919A (ko) | 보습영양제를 함유한 하이드로겔 마스크 및 그 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20080917 |